March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Long Term Evaluation of the Visual Prognosis in Patients Treated With Dexamethasone Intravitreal Implant (Ozurdex) for Macular Edema Due to Retinal Vein Occlusion
Author Affiliations & Notes
  • Elad Moisseiev
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Michaella Goldstein
    Ophthalmology, Tel-Aviv Medical Center, Tel-Aviv, Israel
  • Michael Waisbourd
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Adiel Barak
    Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel
  • Anat Loewenstein
    Ophthalmology, Tel-Aviv Medical Center, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships  Elad Moisseiev, None; Michaella Goldstein, Allergan (R); Michael Waisbourd, None; Adiel Barak, Allergan (R); Anat Loewenstein, Allergan, Forsightlabs, Lumenis, NotalVision, Orabio. (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6928. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elad Moisseiev, Michaella Goldstein, Michael Waisbourd, Adiel Barak, Anat Loewenstein; Long Term Evaluation of the Visual Prognosis in Patients Treated With Dexamethasone Intravitreal Implant (Ozurdex) for Macular Edema Due to Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2012;53(14):6928.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the long-term visual prognosis and complications of patients who received intravitreal Ozurdex injections for the treatment of macular edema (ME) due to retinal vein occlusion (RVO).

 
Methods:
 

Patients who received Ozurdex injections in our institution as part of the GENEVA study were recalled for examination. Initial and final visual acuity (VA), intraocular pressure (IOP) and retinal thickness by OCT were compared. The occurrence of complications and administration of additional treatments for ME were recorded.

 
Results:
 

17 patients were followed for a mean of 50.5 months. Patients with branch RVO had a more favorable prognosis than central RVO, and their mean VA had improved significantly, whereas the mean VA for the patients with central RVO did not improve significantly (Figure). Retinal thickness had reduced significantly in the whole group and in each subgroup separately. Complications included 10 patients with cataract progression, 1 with elevated IOP and 1 with neovascularisation and vitreous hemorrhage. Additional treatments were administered in 53% of patients.

 
Conclusions:
 

This is the first reported long term evaluation of patients treated with Ozurdex. Our results indicate it is well tolerated with an excellent long term safety profile, with cataract progression being the most common complication over time. Long term efficacy was lower than that previously reported in the short term, but this is probably due to the fact that treatment was not repeated throughout the follow-up period. Eventhough, patients with branch RVO treated with Ozurdex had a better visual prognosis than that expected from the known natural history without any intervention. Further research regarding the optimal retreatment schedule for Ozurdex and comparison of its efficacy with other treatment modalities are required.  

 
Keywords: vascular occlusion/vascular occlusive disease • macula/fovea • edema 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×